The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* The prediction of extent and risk profile of coronary atherosclerosis based on clinical evaluation and non-invasive techniques.
* Detailed analysis of plaque volume, plaque composition, risk plaque features and shear stress (WSS) changes during lipid lowering therapy (rosuvastatin 40mg) from 3D vessel reconstruction.
* Prediction of changes in coronary arteries based on changes in non-invasive examinations.
* Examination of WSS influence on atherosclerosis development and changes of WSS during lipid lowering therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease

NCT06936111

Coronary Heart Disease (CHD)

RECRUITING

OFDI-Quantified Intracoronary Thrombus, Antiplatelet Pretreatment Effect and Myocardial Reperfusion

NCT03342521

Myocardial Infarction Thrombosis, Coronary

COMPLETED

Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes

NCT01353612

Atherosclerosis

COMPLETED

Prediction of Atherosclerotic Plaque Progression

NCT05424705

Coronary Artery Disease

ACTIVE_NOT_RECRUITING

Comprehensive Assessment of Morphometric, Functional, Biomechanical and Biological Interactions Between Atherosclerotic Plaque and Platelets Within the Stenosed Coronary Artery

NCT06275399

Chronic Coronary Syndrome Atherosclerosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The fundamental aim of this project is development of reliable algorithm for detection of extent and risk profile of coronary atherosclerosis based on non-invasive examinations (carotid ultrasound, examination of retinal vessel, diagnosis of endothelial dysfunction, pro-inflammatory markers including new markers of atherosclerosis and gene polymorphisms) with maximal effort on diagnosis of vulnerable plaques. The second part of the study is prediction of coronary atherosclerosis changes during high-dose lipid-lowering therapy (rosuvastatin 40 mg daily). Coronary artery impairment will be examined by up-to date technology using the fusion of angiography, intravascular ultrasound and virtual histology for 3D coronary artery reconstruction together with information about mechanical properties of arteries like a vessel shear stress. This algorithm for non-invasive assessment of coronary impairment and its changes during will be used for detection of high risk patients (in terms of acute coronary syndrome development) and of patients with low response to statin therapy. Further target is detailed assessment of atherosclerosis development and its changes during lipid-lowering therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rosuvastatin

All patients will be using rosuvastatin 40 mg

Group Type EXPERIMENTAL

Rosuvastatin

Intervention Type DRUG

All patients will be using rosuvastatin 40 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosuvastatin

All patients will be using rosuvastatin 40 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stable angina pectoris

Exclusion Criteria

* age less than 18 or more than 80
* renal insufficiency
* liver insufficiency
* pregnancy or , child potential without contraception
* intolerance of statins
* rhabdomyolysis or other myopathy in patient´s history
* acute coronary syndrome in last 6 weeks
* coronary anatomy unsuitable for intravascular ultrasound
* active cancer

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No